Recombinant FAST Polypeptides for Targeted Liposome Fusion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current liposome-based delivery systems for bioactive molecules suffer from thermodynamic unfavorability of membrane fusion and cytotoxic effects, leading to non-specific release of encapsulated molecules in both cancerous and healthy cells, necessitating the development of a safer and more targeted delivery method.
Innovation Solution
A recombinant polypeptide comprising an ectodomain with a myristoylation motif, a transmembrane domain with specific hydrophobic β-branched residues and serine glycine junction, and an endodomain, which induces membrane fusion when embedded in liposomes, facilitating targeted delivery of siRNA to cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Strength
If chemicals or lipids are used to promote membrane fusion, then membrane fusion is enhanced, but cytotoxic effects increase
Solution Approach 1:
The patent uses fusion-associated small transmembrane (FAST) proteins as intermediary agents to mediate membrane fusion between liposomes and target cells. These proteins are naturally occurring fusogenic proteins that enable membrane fusion without the cytotoxic side effects of chemical reagents. The FAST proteins are incorporated into the liposome membrane, where they act as mediators to facilitate specific cell-cell fusion while maintaining cell viability.
2Quantity of substance
If traditional liposome-based delivery systems are used, then encapsulated molecules are delivered, but non-specific release occurs in both cancerous and healthy cells
Solution Approach 1:
The patent applies local quality by incorporating specific FAST proteins into the liposome membrane that provide targeted recognition capabilities. Different FAST proteins can be selected or engineered to recognize specific cell surface markers on cancer cells, thereby conferring localized targeting properties to the liposome delivery system. This ensures that the encapsulated bioactive molecules are released specifically at the target site rather than non-specifically throughout the tissue.
3Device complexity
If membrane fusion is attempted under physiological conditions without protein mediation, then the process is simpler, but fusion efficiency is low due to thermodynamic unfavorability
Solution Approach 1:
The patent employs FAST proteins that possess intrinsic fusogenic activity, allowing the liposome system to achieve efficient membrane fusion through the inherent properties of the incorporated proteins. The FAST proteins contain hydrophobic regions that spontaneously insert into target cell membranes and facilitate fusion without requiring external energy input or complex machinery. This self-service mechanism maintains relative simplicity while achieving high fusion efficiency under physiological conditions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The recombinant polypeptide enhances membrane fusion and syncytia formation, enabling targeted delivery of siRNA with reduced cytotoxicity and improved specificity to cancer cells.
Implementation Method 1
an N-terminal hydrophobic patch, comprised of the first 21 residues
Implementation Method 2
a transmembrane domain, comprised of 23 amino acid residues, at least two N-terminal hydrophobic, β-branched residues adjacent the ectodomain
Data Source
AI summary
Disclosed is a recombinant polypeptide for facilitating membrane fusion. The recombinant polypeptide having a sequence with at least 80% sequence identity with the ectodomain of p14 fusion-associated small transmembrane (FAST) protein and having a functional myristoylation motif, a transmembrane domain from a FAST protein and a sequence with at least 80% sequence identity with the endodomain of p15 FAST protein. A targeting ligand can be added to the recombinant polypeptide for selective fusion. The recombinant polypeptide can be included in the membrane of a liposome, or the like, to facilitate the delivery of bioactive compounds, such as siRNA, or the recombinant polypeptide can be mixed with a lipid carrier and added to cultured cells to induce cell-cell fusion and heterokaryon formation.